Update on trametinib (Mekinist) for low grade serous ovarian cancer

[OvacomeSupport]

Good morning everyone

We are delighted that NHS England has recommended that the MEK-inhibitor trametinib (Mekinist) should be routinely available as an off-label treatment option for adults with recurrent or progressive low grade serous ovarian cancer (LGSOC). This is for people who have received platinum-based chemotherapy previously and have not had treatment with a MEK-inhibitor in the past.

Trametinib is a targeted therapy which blocks a protein that helps cancer cells grow.

Off-label drugs are prescribed by doctors in a different way than the conditions in its licence. Trametinib is not currently licenced for LGSOC but it has been available through clinical trials and as part of the Cancer Drugs Fund. We welcome NHS England’s decision to recognise the potential benefit for those diagnosed with LGSOC and offer a further routine treatment choice for this group.

You can read more about LGSOC in our booklet here: ovacome.org.uk/low-grade-bo...

There are further details about this decision from NHS England here: england.nhs.uk/publication/...

If you have any questions or would like to talk things through, please don't hesitate to get in touch. You can send us a direct message here on the forum, email [e-mail] or call our Freephone support line on 0800 008 7054. We're here to support you, Monday - Friday, 10am - 5pm.

Best wishes

Annie - Ovacome Support